Status:
UNKNOWN
Effects of Oral Care With Glutamine on Oral Health, Oral Flora and Incidence of Pneumonia After Neurosurgery With Microbiome Analysis
Lead Sponsor:
Yanzhao
Conditions:
Oral Mucositis
Pneumonia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
A randomized, double-blind, single-center and controlled study comparing the efficacy and safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous bilateral total k...
Detailed Description
A randomized, double-blind, single-center and controlled study comparing the efficacy and safety of intravenous administration of tranexamic acid to reduce blood loss in simultaneous bilateral total k...
Eligibility Criteria
Inclusion
- Adult patients who plan to undergo simultaneous primary total knee arthroplasty on bilateral knee joint with a diagnosis of osteoarthritis or aseptic bone necrosis, but not of rheumatoid arthritis;
- All patients who have normal preoperative platelet count, normal prothrombin time, normal partial thromboplastin time, and normal international normalized ratio;
- The use of only balanced electrolyte solutions and/or albumin for plasma volume restitution.
Exclusion
- Allergy to tranexamic acid;
- Receiving warfarin or heparin; had a history of hemophilia, deep venous thrombosis, pulmonary embolism, or renal impairment; or were pregnant;
- Patients with any cardiovascular problems (such as myocardiac infarction history, atrial fibrillation, angina);
- Patients with thromboembolic disorders, or those exhibiting a deteriorating general condition;
- Preoperative anemia (a hemoglobin value of \<11 g/dL in females and \<12 g/dL in males), refusal of blood products;
- Preoperative use of anticoagulant therapy within five days before surgery, fibrinolytic disorders requiring intraoperative antifibrinolytic treatment, coagulopathy (as identified by a preoperative platelet count of \<150,000/mm3, an international normalized ratio of \>1.4, or a prolonged partial thromboplastin time \[\>1.4 times normal\]).
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03867214
Start Date
January 1 2019
End Date
March 1 2024
Last Update
April 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital
Xi'an, China